<unk> , sold under the brand name Qinlock, is a medication for the treatment of adults with advanced gastrointestinal stromal tumor (GIST), a type of tumor that originates in the gastrointestinal tract. It is taken by mouth.<unk>  inhibits the activity of the kinases KIT and PDGFRA, which helps keep cancer cells from growing. The most common side effects include alopecia (hair loss), fatigue, nausea, abdominal pain, constipation, myalgia (muscle pain), diarrhea, decreased appetite, palmar-plantar erythrodysesthesia syndrome (a skin reaction in the palms and soles) and vomiting.<unk>  was approved for medical use in the United States in May 2020, in Australia in July 2020, and in the European Union in November 2021.<unk>  is the first new drug specifically approved in the United States as a fourth-line treatment for advanced gastrointestinal stromal tumor (GIST).
Ripretinib
Sotorasib
Duvelisib
Copanlisib
Idelalisib
Vosoritide
Triptorelin
Progabide